2fpy
From Proteopedia
(New page: 200px<br /> <applet load="2fpy" size="450" color="white" frame="true" align="right" spinBox="true" caption="2fpy, resolution 2.000Å" /> '''Dual binding mode ...) |
|||
| Line 1: | Line 1: | ||
| - | [[Image:2fpy.gif|left|200px]]<br /> | + | [[Image:2fpy.gif|left|200px]]<br /><applet load="2fpy" size="350" color="white" frame="true" align="right" spinBox="true" |
| - | <applet load="2fpy" size=" | + | |
caption="2fpy, resolution 2.000Å" /> | caption="2fpy, resolution 2.000Å" /> | ||
'''Dual binding mode of a novel series of DHODH inhibitors'''<br /> | '''Dual binding mode of a novel series of DHODH inhibitors'''<br /> | ||
==Overview== | ==Overview== | ||
| - | Human dihydroorotate dehydrogenase (DHODH) represents an important target | + | Human dihydroorotate dehydrogenase (DHODH) represents an important target for the treatment of hyperproliferative and inflammatory diseases. In the cell DHODH catalyzes the rate-limiting step of the de novo pyrimidine biosynthesis. DHODH inhibition results in beneficial immunosuppressant and antiproliferative effects in diseases such as rheumatoid arthritis. Here, we present high-resolution X-ray structures of human DHODH in complex with a novel class of low molecular weight compounds that inhibit the enzyme in the nanomolar range. Some compounds showed an interesting dual binding mode within the same cocrystal strongly depending on the nature of chemical substitution. Measured in vitro activity data correlated with the prevailing mode of binding and explained the observed structure-activity relationship. Additionally, the X-ray data confirmed the competitive nature of the inhibitors toward the putative ubiquinone binding site and will guide structure-based design and synthesis of molecules with higher activity. |
==About this Structure== | ==About this Structure== | ||
| - | 2FPY is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with ACT, SO4, FMN, ORO and ILF as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Dihydroorotate_oxidase Dihydroorotate oxidase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.3.3.1 1.3.3.1] Full crystallographic information is available from [http:// | + | 2FPY is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=ACT:'>ACT</scene>, <scene name='pdbligand=SO4:'>SO4</scene>, <scene name='pdbligand=FMN:'>FMN</scene>, <scene name='pdbligand=ORO:'>ORO</scene> and <scene name='pdbligand=ILF:'>ILF</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Dihydroorotate_oxidase Dihydroorotate oxidase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.3.3.1 1.3.3.1] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2FPY OCA]. |
==Reference== | ==Reference== | ||
| Line 24: | Line 23: | ||
[[Category: protein inhibitor complex]] | [[Category: protein inhibitor complex]] | ||
| - | ''Page seeded by [http:// | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 17:23:59 2008'' |
Revision as of 15:24, 21 February 2008
|
Dual binding mode of a novel series of DHODH inhibitors
Overview
Human dihydroorotate dehydrogenase (DHODH) represents an important target for the treatment of hyperproliferative and inflammatory diseases. In the cell DHODH catalyzes the rate-limiting step of the de novo pyrimidine biosynthesis. DHODH inhibition results in beneficial immunosuppressant and antiproliferative effects in diseases such as rheumatoid arthritis. Here, we present high-resolution X-ray structures of human DHODH in complex with a novel class of low molecular weight compounds that inhibit the enzyme in the nanomolar range. Some compounds showed an interesting dual binding mode within the same cocrystal strongly depending on the nature of chemical substitution. Measured in vitro activity data correlated with the prevailing mode of binding and explained the observed structure-activity relationship. Additionally, the X-ray data confirmed the competitive nature of the inhibitors toward the putative ubiquinone binding site and will guide structure-based design and synthesis of molecules with higher activity.
About this Structure
2FPY is a Single protein structure of sequence from Homo sapiens with , , , and as ligands. Active as Dihydroorotate oxidase, with EC number 1.3.3.1 Full crystallographic information is available from OCA.
Reference
Dual binding mode of a novel series of DHODH inhibitors., Baumgartner R, Walloschek M, Kralik M, Gotschlich A, Tasler S, Mies J, Leban J, J Med Chem. 2006 Feb 23;49(4):1239-47. PMID:16480261
Page seeded by OCA on Thu Feb 21 17:23:59 2008
Categories: Dihydroorotate oxidase | Homo sapiens | Single protein | Baumgartner, R. | Leban, J. | ACT | FMN | ILF | ORO | SO4 | Protein inhibitor complex
